A Mab A Case Study | In Bioprocess Development |best|

The TPP required 100 mg/mL in a liquid formulation. At this concentration, A Mab exhibited:

This case study demonstrates that a modern mAb process is not developed linearly. By integrating upstream media chemistry (clone #47B + metal modulation) with downstream flocculation and high-resilience Protein A capture, the team transformed a problematic, aggregate-prone mAb (initial yield <1.5 g/L recoverable) into a robust 6.1 g/L titer process with a 71% final recovery. The drug product met all Phase I release specifications for purity, potency, and safety. A Mab A Case Study In Bioprocess Development

The traditional "batch" mindset—where processes are a series of discrete, start-stop steps—is giving way to a more integrated, continuous paradigm. This shift is perhaps the most significant trend in bioprocessing, promising smaller facility footprints, lower capital costs, and increased agility. The development story of A-mAb concludes with a look at this horizon, as exemplified by the . The TPP required 100 mg/mL in a liquid formulation

The tech transfer succeeded after three engineering runs, with yield within 95–102% of pilot scale. The drug product met all Phase I release

Develop a robust process capable of seamless technology transfer to a 2,000L pilot facility.

Using a 0.2 cm bed height of multimodal resin (Capto Adhere) at pH 5.5.